180 Life Sciences Corp.
ATNF
$1.05
-$0.03-2.78%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -52.94% | -21.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -46.98% | -11.75% | |||
| Operating Income | 46.98% | 11.75% | |||
| Income Before Tax | -7,190.68% | 101.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7,190.68% | 101.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7,190.68% | 101.10% | |||
| EBIT | 46.98% | 11.75% | |||
| EBITDA | 47.05% | 11.90% | |||
| EPS Basic | -6,765.63% | 100.76% | |||
| Normalized Basic EPS | -464.34% | 90.58% | |||
| EPS Diluted | -8,632.00% | 100.60% | |||
| Normalized Diluted EPS | -464.34% | 90.58% | |||
| Average Basic Shares Outstanding | 6.69% | 43.99% | |||
| Average Diluted Shares Outstanding | 6.69% | 43.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
